GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Shiller PE Ratio

Lipocine (Lipocine) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lipocine Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lipocine Shiller PE Ratio Historical Data

The historical data trend for Lipocine's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Shiller PE Ratio Chart

Lipocine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lipocine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lipocine's Shiller PE Ratio

For the Biotechnology subindustry, Lipocine's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lipocine's Shiller PE Ratio falls into.



Lipocine Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lipocine's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Lipocine's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.66/131.7762*131.7762
=0.660

Current CPI (Mar. 2024) = 131.7762.

Lipocine Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -9.350 100.560 -12.253
201409 -5.440 100.428 -7.138
201412 -5.440 99.070 -7.236
201503 -3.910 99.621 -5.172
201506 -4.420 100.684 -5.785
201509 -5.950 100.392 -7.810
201512 -4.318 99.792 -5.702
201603 -6.460 100.470 -8.473
201606 -5.440 101.688 -7.050
201609 -3.060 101.861 -3.959
201612 -2.720 101.863 -3.519
201703 -4.420 102.862 -5.662
201706 -5.270 103.349 -6.720
201709 -3.740 104.136 -4.733
201712 -4.250 104.011 -5.385
201803 -2.210 105.290 -2.766
201806 -2.550 106.317 -3.161
201809 -2.040 106.507 -2.524
201812 -2.550 105.998 -3.170
201903 -2.380 107.251 -2.924
201906 -2.380 108.070 -2.902
201909 -2.040 108.329 -2.482
201912 -1.700 108.420 -2.066
202003 -2.380 108.902 -2.880
202006 -2.210 108.767 -2.678
202009 -1.190 109.815 -1.428
202012 -1.020 109.897 -1.223
202103 -0.680 111.754 -0.802
202106 -1.360 114.631 -1.563
202109 -0.680 115.734 -0.774
202112 2.380 117.630 2.666
202203 -0.680 121.301 -0.739
202206 -0.610 125.017 -0.643
202209 -0.520 125.227 -0.547
202212 -0.430 125.222 -0.453
202303 -0.760 127.348 -0.786
202306 -0.680 128.729 -0.696
202309 -1.270 129.860 -1.289
202312 -0.420 129.419 -0.428
202403 0.660 131.776 0.660

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lipocine  (NAS:LPCN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lipocine Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lipocine's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine (Lipocine) Business Description

Traded in Other Exchanges
N/A
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Executives
Mahesh V. Patel director, officer: President and CEO C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono director 18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos director C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos officer: Chief Medical Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty officer: Principal Accounting Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi director C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown officer: EVP and CFO 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink director 2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass officer: EVP and Chief Commercial Offic 3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila officer: Chief Business Officer AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran officer: CTO and VP RandD C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell officer: VP Finance C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons officer: VP Corp Business Development 837 4TH AVE, SALT LAKE CITY UT 84103